Half-year report · HY
7745.TEDINET S100X328
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥30.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥67.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥30.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥3.2bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.3bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥9.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.8bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥69.3bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥69.0bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥66.7bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥25.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥26.2bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥44.2bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥42.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥38.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥13.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥62.25 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥235.63 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.38 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥62.19 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥235.41 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.32 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 63.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 99
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥13.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥13.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥799m |
| America Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥2.4bn |
| America Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.4bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥52m |
| America Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥1m |
| America Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| America Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4m |
| America Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥139m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥4.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.9bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.7bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥328m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥4.0bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥277m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3.7bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥85m |
| Europe Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥285m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥285m |
| Europe Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥14m |
| Europe Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥4.4bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥4.4bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Europe Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥24m |
| Japan Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥9.9bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥7.9bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥366m |
| Japan Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥8.1bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.1bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.5bn |
| Japan Semiconductor Relatedreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Japan Semiconductor Relatedreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Japan Semiconductor Relatedreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4m |
| Japan Semiconductor Relatedreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.6bn |
| Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥17.2bn |
| Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥13.5bn |
| Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3.7bn |
| Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥679m |
| Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥21.6bn |
| Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥11.8bn |
| Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥9.8bn |
| Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.7bn |
| Semiconductor Related Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Semiconductor Related Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Semiconductor Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4m |
| Semiconductor Related Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥14.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥14.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.2bn |
| America Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| America Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥156m |
| America Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥65m |
| America Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| America Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1m |
| America Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥144m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.8bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥307m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.8bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥229m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥199m |
| Europe Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥346m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥346m |
| Europe Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Europe Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥0 |
| Europe Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Europe Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥221m |
| Japan Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥9.4bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥301m |
| Japan Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥8.7bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Japan Semiconductor Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| Japan Semiconductor Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| Japan Semiconductor Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥16.8bn |
| Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.3bn |
| Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥543m |
| Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥22.5bn |
| Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥11.7bn |
| Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥10.9bn |
| Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| Semiconductor Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| Semiconductor Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| Semiconductor Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 620
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes changes in scope of consolidation or equity method (text) | InterimDuration | Text · Plus | |
| Notes accounting treatments specific to semi annual financial statements type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes regarding allowances directly deducted from balances of assets (text) | InterimInstant | Text · Plus | |
| Notes regarding financial covenants (text) | InterimInstant | Text · Plus | |
| Allowance for loss related to measurement act (text) | InterimDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Provision for loss related to the measurement act (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |